Crumly & Associates’s First Trust NYSE Arca Biotechnology Index Fund FBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
– Sell
-5,691
Closed -$849K – 113
2022
Q1
$849K Sell
5,691
-1,983
-26% -$293K 0.32% 50
2021
Q4
$1.13M Sell
7,674
-11,039
-59% -$1.79M 0.45% 42
2021
Q3
$3.11M Sell
18,713
-543
-3% -$92.8K 1.44% 20
2021
Q2
$3.32M Sell
19,256
-15,947
-45% -$2.63M 1.61% 20
2021
Q1
$5.65M Sell
35,203
-3,042
-8% -$521K 3.3% 11
2020
Q4
$6.91M Buy
38,245
+4,033
+12% +$654K 4.85% 5
2020
Q3
$5.38M Buy
34,212
+7,760
+29% +$1.27M 4.6% 6
2020
Q2
$4.44M Buy
26,452
+4,097
+18% +$643K 4.16% 9
2020
Q1
$2.93M Sell
22,355
-5,816
-21% -$829K 3.6% 10
2019
Q4
$4.19M Buy
+28,171
New +$3.87M 4.34% 9

Other funds holding FBT

Crumly & Associates's FBT Position: Q2 2022 in Review

Crumly & Associates sold out of First Trust NYSE Arca Biotechnology Index Fund (FBT) in Q2 2022, closing a stake of 5,691 shares — an estimated $849K sold.

Crumly & Associates first reported a position in FBT in Q4 2019 and held it in 10 quarters. The position peaked at $6.91M in Q4 2020. 223 funds tracked by Wall St. Rank hold FBT as of Q2 2022.

  • Crumly & Associates reported no remaining First Trust NYSE Arca Biotechnology Index Fund position as of Q2 2022 after selling out during the quarter.
  • Crumly & Associates sold 5,691 First Trust NYSE Arca Biotechnology Index Fund shares in Q2 2022, an estimated $849K.
  • Crumly & Associates first reported a position in First Trust NYSE Arca Biotechnology Index Fund in Q4 2019 and held it in 10 quarters.
  • Crumly & Associates's First Trust NYSE Arca Biotechnology Index Fund position peaked at $6.91M in Q4 2020.
  • 223 funds tracked by Wall St. Rank held First Trust NYSE Arca Biotechnology Index Fund as of Q2 2022.

Based on Crumly & Associates's 13F filing for Q2 2022, filed 1 Aug 2022.